European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

Santa Lucia Foundation IRCCS-led research is reporting that repetitive transcranial magnetic stimulation (rTMS) targeting the ...

A new scientific breakthrough may soon offer hope for people affected by Alzheimer’s disease. A group of researchers in Spain ...

A study published in The American Journal of Human Genetics by researchers at Baylor College of Medicine and the Jan and Dan ...

Key takeaways Cholesterol regulation and neuronal vulnerability: The study found that neurons in the locus coeruleus (LC)—a ...

The Trump administration is freezing, delaying and revoking funding for dementia research, setting back discoveries of ...

Leqembi approved by the EU for early-stage Alzheimer’s in patients with specific ApoE4 gene profile, marking a milestone in ...

Alzheimer’s disease has long eluded treatment. Attempts to tackle it by targeting the amyloid-β protein that accumulates in the brains of people with the condition have often foundered on the ...

The study supports prior research that found the same thing.

The antibody lecanemab is the first authorized therapy in Europe that targets the underlying process of Alzheimer's, rather than only treating symptoms.

NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern ...

The family of an elderly Coleraine woman with Alzheimer’s have raised concerns about the care she received at an NI hospital.